Levofloxacin (Levaquin) is NOT FDA-approved for use in a 17-year-old female with sinusitis.
The FDA label explicitly states that levofloxacin is indicated only for adults ≥18 years of age for acute bacterial sinusitis 1. At 17 years old, this patient falls outside the approved age range for this indication.
Pediatric Use Restrictions
The FDA has approved levofloxacin in pediatric patients (≥6 months) for only two specific indications 1:
- Inhalational anthrax (post-exposure)
- Plague treatment and prophylaxis
Acute bacterial sinusitis is not among the approved pediatric indications, even though levofloxacin has been studied in children for other respiratory infections 2.
Why This Matters
Fluoroquinolones cause arthropathy and osteochondrosis in juvenile animals, and pediatric patients treated with levofloxacin have shown significantly higher rates of musculoskeletal disorders (primarily arthralgia involving weight-bearing joints) compared to non-fluoroquinolone-treated children 1. While most cases were mild to moderate and resolved without sequelae, this safety concern restricts pediatric use to life-threatening infections where benefits clearly outweigh risks.
Appropriate Treatment for This Patient
For a 17-year-old with acute bacterial sinusitis, use amoxicillin or amoxicillin-clavulanate as first-line therapy 3:
- Mild-to-moderate, uncomplicated cases: Amoxicillin 45 mg/kg/day divided twice daily
- High-risk features (child care attendance, recent antibiotics, age <2 years, or moderate-to-severe illness): High-dose amoxicillin-clavulanate 80-90 mg/kg/day (of amoxicillin component) with 6.4 mg/kg/day clavulanate, divided twice daily, maximum 2 g per dose 3
For treatment failures or penicillin allergy, consider ceftriaxone, clindamycin plus cefixime, or linezolid plus cefixime 3. Levofloxacin appears only as a last-resort option in the pediatric sinusitis guideline algorithm for refractory cases 3, but this would be off-label use requiring careful risk-benefit consideration.
Common Pitfall
Do not assume that because a patient is "almost 18" they can receive adult-approved medications. FDA age restrictions are based on safety data, and the musculoskeletal risks in developing adolescents remain a concern until skeletal maturity.